Current Rheumatology Reports

, Volume 12, Issue 5, pp 342–347

Measurement of Erythrocyte Methotrexate Polyglutamate Levels: Ready for Clinical Use in Rheumatoid Arthritis?

  • Maria I. Danila
  • Laura B. Hughes
  • Elizabeth E. Brown
  • Sarah L. Morgan
  • Joseph E. Baggott
  • Donna K. Arnett
  • S. Louis BridgesJr
Article

DOI: 10.1007/s11926-010-0120-3

Cite this article as:
Danila, M.I., Hughes, L.B., Brown, E.E. et al. Curr Rheumatol Rep (2010) 12: 342. doi:10.1007/s11926-010-0120-3

Abstract

Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of low-dose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.

Keywords

Rheumatoid arthritis Methotrexate Polyglutamates 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Maria I. Danila
    • 1
  • Laura B. Hughes
    • 1
  • Elizabeth E. Brown
    • 1
  • Sarah L. Morgan
    • 1
  • Joseph E. Baggott
    • 1
  • Donna K. Arnett
    • 1
  • S. Louis BridgesJr
    • 1
  1. 1.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations